8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report  (Date of earliest event reported):   February 1, 2005

_________________

CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)

_________________

FLORIDA	1-13165	59-2417093
(State or Other Jurisdiction       of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1655 ROBERTS BOULEVARD, N.W., KENNESAW, GEORGIA 30144
(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code:   (770) 419-3355

_____________________________________________________________________
(Former name or former address, if changed since last report)

_________________

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01   Other Events.

On February 1, 2005, CryoLife, Inc. (“CryoLife”) issued a press release announcing that it received accreditation from the American Association of Tissue Banks (AATB). CryoLife hereby incorporates by reference herein the information set forth in its Press Release dated February 1, 2005, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01   Financial Statements and Exhibits.

        (a)        Financial Statements.

        (b)        Pro Forma Financial Information.

        (c)        Exhibits.

Exhibit Number	Description
99.1	Press Release dated February 1, 2005

2

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CRYOLIFE, INC.
Date:   February 1, 2005	By:  /s/ D. A. Lee Name: D. Ashley Lee Title: Executive Vice President, Chief Operating Officer and Chief Financial Officer

3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated February 1, 2005

EX-99.1

FOR IMMEDIATE RELEASE

Contact: Joseph T. Schepers
Vice President, Corporate Communications
(770) 419-3355

CRYOLIFE RECEIVES AMERICAN ASSOCIATION OF TISSUE BANKS (AATB)  ACCREDITATION

ATLANTA (February 1, 2005) – CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it received accreditation from the American Association of Tissue Banks (AATB). The AATB is a scientific, not-for-profit peer group organization that facilitates the provision of high quality transplantable human tissues in quantities sufficient to meet national needs.

“CryoLife is pleased to join the AATB, which is highly regarded and recognized within the tissue banking industry and medical community. For over twenty years, CryoLife has served as a technological bridge between donor families and allograft recipients. CryoLife is dedicated to improving the health and quality of life around the world through tissue transplantation and its biosurgical adhesive, BioGlue. Since the Company was founded in 1984, more than 100,000 CryoLife-processed human tissues have been implanted in patients,” said Steven G. Anderson, CryoLife President and Chief Executive Officer.

“CryoLife is one of the largest tissue processors in the country with an extensive history of providing innovative tissue technologies to the transplant community and we welcome them as a member of the AATB,” stated P. Robert Rigney, Jr., J.D., Chief Executive Officer of AATB.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company’s BioGlue^® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels, and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SG Model #100 vascular graft, which is CE marked for distribution within the European Community.

END